Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia by Benjamin M. Heyman, Stephen S. Opat, Björn E. Wahlin, Meletios-Athanasios C. Dimopoulos, Jorge J. Castillo, Alessandra Tedeschi, Constantine S. Tam, Christian Buske, Roger G. Owen, Véronique Leblond, Judith Trotman, Gisoo Barnes, Wai Y. Chan, Jingjing Schneider, Heather Allewelt, Aileen Cohen, Jeffrey V. Matous

Get full text

CHAT-S study protocol: A randomized controlled trial of a health insurance literacy education program for young adult cancer survivors by Mary Killela, Cindy A. Turner, Amy Chevrier, Monique Stefanou, Perla L. Vaca Lopez, Heydon K. Kaddas, Karely M. van Thiel Berghuijs, Echo L. Warner, Giselle K. Perez, Austin R. Waters, Douglas B. Fair, Richard E. Nelson, Mark A. Lewis, Elyse R. Park, Anne C. Kirchhoff

“…We will enroll 300 YA cancer survivors (n = 200 intervention; n = 100 usual care) diagnosed with breast, testicular, lymphoma, sarcoma, colorectal, melanoma, or thyroid cancer between the ages of 26 and 39, who have completed treatment in the past two years. …”
Get full text

A national population-based study of mortality and risk factors in COVID-19-hospitalized patients in Spain (2020–2021) by José-Manuel Ramos-Rincón, José-Manuel Ramos-Rincón, José Sánchez-Paya, Pilar González-De-La-Aleja, Juan-Carlos Rodríguez-Díaz, Juan-Carlos Rodríguez-Díaz, Esperanza Merino, Esperanza Merino

“…Risk factors for IHM remained consistent, with leukemia, neoplasm, and lymphoma posing the highest risks, while female sex (AOR: 0.75, 95% CI: 0.74–0.77, p < 0.001) and dyslipidemia (AOR: 0.85, 95% CI: 0.32–0.86, p < 0.001) were protective factors.ConclusionDuring the vaccination period, the risk of in-hospital mortality (IHM) was 29% lower than in the prevaccination period, after adjusting for sex, age, and comorbidities. …”
Get full text

Kefir Prevents Adipose Tissue Growth Through the Induction of Apoptotic Elements in High-Fructose Corn Syrup-Fed Rats by Esra Aslan, Gokhan Sadi, Hilal Guzel, Cigdem Karaca, Omer Adil Korkmaz, Mine Kanat Pektas, Mehmet Celegen, Tugce Aladag, Seyma Oncu, Mehmet Bilgehan Pektas

“…Increased expression of Akt and B-cell lymphoma-2 gene ( Bcl2 ) was contrasted with decreased expression of Nfkb, Tnfa , tumor protein 53 gene ( p53 ), and caspase-8 gene ( Casp8 ). …”
Get full text

Malignancies in people living with HIV: A 25-years observational study from a tertiary hospital in Italy by Antonio Anastasia, Walter Mazzucco, Luca Pipitò, Santo Fruscione, Roberta Gaudiano, Marcello Trizzino, Maurizio Zarcone, Antonio Cascio

“…Background: HIV infection has been associated with an increased risk of cancer development and Kaposi’s sarcoma, non-Hodgkin’s lymphoma, and invasive cervical cancers have been a manifestation of AIDS. …”
Get full text

Synthesis and Anti-Cancer Activity In Vitro of Synephrine Derivatives by Ekaterina M. Zhidkova, Evgeniya S. Oleynik, Ekaterina A. Mikhina, Daria V. Stepanycheva, Diana D. Grigoreva, Lyubov E. Grebenkina, Kirill V. Gordeev, Ekaterina D. Savina, Andrey V. Matveev, Marianna G. Yakubovskaya, Ekaterina A. Lesovaya

“…We evaluated <i>in vitro</i> anti-cancer effects in leukemia K562 and lymphoma Granta cells using the MTT assay and studied their potential affinity for the glucocorticoid receptor (GR) <i>in silico</i> using the molecular docking approach. …”
Get full text

Therapeutic effect of dihydroartemisinin on Alzheimer’s disease model mice with senile macular degeneration by Gao Han, Gong Xuewu, Zhang Meng, Wang Yuejing, Wang Yuchun, Zhang Keshuang, Yao Hongbo

“…Compared with the conventional feeding group, autophagy and apoptosis related proteins B-cell lymphoma-2 (BCL2) and anti-thymocyte globulin (ATG) were significantly down regulated in the 5× FAD group, and the expressions of BCL2 and ATG were increased after treatment with DHA and donepezil. …”
Get full text

Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML by Julia M. Unglaub, Richard F. Schlenk, Jan Moritz Middeke, Stefan W. Krause, Sabrina Kraus, Hermann Einsele, Michael Kramer, Sven Zukunft, Joseph Kauer, Simon Renders, Elena Katelari, Christoph Schliemann, Caroline Pabst, Thomas Luft, Peter Dreger, Christoph Röllig, Martin Bornhäuser, Carsten Müller-Tidow, Tim Sauer

“…Abstract: The B-cell lymphoma 2 inhibitor venetoclax (VEN) in combination with hypomethylating agents has been approved for first-line treatment of patients with acute myeloid leukemia (AML) ineligible for intensive treatment. …”
Get full text

Endothelial Activation and Stress Index (EASIX) to predict mortality after allogeneic stem cell transplantation: a prospective study by Axel Benner, Peter Dreger, Grzegorz W Basak, Christian Koenecke, Olaf Penack, Christophe Peczynski, Lucia López Corral, Ivan Moiseev, Hélène Schoemans, Zinaida Peric, Thomas Luft, Simona Sica, Mutlu Arat, Maija Itäla-Remes, Nicolaas P M Schaap, Michal Karas, Ludek Raida, Thomas Schroeder, Elisabetta Metafuni, Tulay Ozcelik, Brenda M Sandmaier, Lambros Kordelas

“…For cut-off validation, we conducted a multicenter prospective study with inclusion of n=317 first alloSCTs from peripheral blood stem cell in adult patients with acute leukemia, lymphoma or myelodysplastic syndrome/myeloproliferative neoplasms in the European Society for Blood and Marrow Transplantation network.Results Twenty-three % (n=74) of alloSCT recipients had EASIX-pre ≥3 taken before conditioning. …”
Get full text

Preimplantation genetic testing for aneuploidy in severe male factor infertility: protocol for a multicenter randomised controlled trial by Li Wang, Li Jin, Yao Lu, Chen Zhang, He-Feng Huang, Yun Sun, Xian-hua Lin, Meng-xi Guo, Dan-dan Wu, Jian-lin Zhang, Cheng-liang Zhou, Chen-ming Xu, Song-chang Chen, Song-ying Zhang, Xiao-xi Sun, Yan-ting Wu

Get full text

Non-classical pulmonary exacerbation in cystic fibrosis revealing ALK-Translocated lung cancer: A case report by Mohamad Hadhud, Johnathan Arnon, Anat Hershko-Moshe, Adi Hollander, Noa Hurvitz-Lehmann, Assaf Potruch, Henny Azmanov, Rottem Kuint, Nurith Hiller, Elie Picard, Naama Sebbag-Sznajder, Shira Leebhoff, Michael Wilschanski, Myriam Grunewald, Liron Birimberg-Schwartz, Malena Cohen-Cymberknoh

“…The patient was subsequently diagnosed with non-small cell lung carcinoma (NSCLC), featuring anaplastic lymphoma kinase (ALK) translocation. Following treatment with a targeted tyrosine kinase inhibitor (TKI) there was a rapid tumor regression, however, his dyspnea and hypoxemia subsequently worsened. …”
Get full text

Preventing sensory and motor dysfunctions in children receiving neurotoxic chemotherapy: PrepAir study - an update by Céline Hammadou, Bianca Celine Schmidli, Christina Schindera, Nicolas von der Weid, Uta Tacke, Oliver Faude, Sarah Koch, Fiona Streckmann

“…We have so far recruited N=19/131 children and adolescents (Basel: N=6, Freiburg: N=12, Bern: N=1; %f=47.4; mean age= 16.44 years; cancer type 42.1% leukemia ALL, 42.1% lymphoma, 15.8% solid tumor). Discussion/Conclusion We hypothesize that less children in the intervention group will develop symptoms of CIPN and will be able to maintain relevant motor and sensory functions which will enable them to receive their planned medical therapy but also to stay on the age-appropriate motor development level, improve their quality life and enhance social reintegration after therapy. …”
Get full text

Ibrutinib disrupts blood-tumor barrier integrity and prolongs survival in rodent glioma model by Sanghee Lim, Minhye Kwak, Jeonghan Kang, Melissa Cesaire, Kayen Tang, Robert W. Robey, William J. E. Frye, Baktiar Karim, Donna Butcher, Martin J. Lizak, Mahalia Dalmage, Brandon Foster, Nicholas Nuechterlein, Charles Eberhart, Patrick J. Cimino, Michael M. Gottesman, Sadhana Jackson

“…Ibrutinib, FDA-approved lymphoma agent, inhibits Bruton tyrosine kinase (BTK) and has previously been shown to independently impair aortic endothelial adhesion and increase rodent glioma model survival in combination with cytotoxic therapy. …”
Get full text

Large-scale manufacturing and characterization of CMV-CD19CAR T cells by Stephen J Forman, Xiuli Wang, Ryan Urak, Miriam Walter, Min Guan, Tianxu Han, Vibhuti Vyas, Sheng-Hsuan Chien, Brenna Gittins, Mary C Clark, Sally Mokhtari, Angelo Cardoso, Don J Diamond, John Zaia, Ryotaro Nakamura

“…We plan to initiate a clinical trial at City of Hope using CMV-CD19CAR T cells for patients with intermediate/high-grade B cell non-Hodgkin’s lymphoma immediately after autologous hematopoietic cell transplantation followed by vaccination with a novel CMV vaccine based on Modified Vaccinia Ankara (Triplex) 28 days and 56 days post-T cell infusion.…”
Get full text

Ultrasound May Suppress Tumor Growth, Inhibit Inflammation, and Establish Tolerogenesis by Remodeling Innatome via Pathways of ROS, Immune Checkpoints, Cytokines, and Trained Immun... by Qian Yang, Ruijing Zhang, Peng Tang, Yu Sun, Candice Johnson, Jason Saredy, Susu Wu, Jiwei Wang, Yifan Lu, Fatma Saaoud, Ying Shao, Charles Drummer, Keman Xu, Daohai Yu, Rongshan Li, Shuping Ge, Xiaohua Jiang, Hong Wang, Xiaofeng Yang

“…We made the following findings: (1) LIUS upregulates proinflammatory IGs and downregulates metastasis genes in cancer cells, and LIUS upregulates adaptive immunity pathways but inhibits danger-sensing and inflammation pathways and promote tolerogenic differentiation in bone marrow (BM) cells. (2) LIUS upregulates IGs encoded for proteins localized in the cytoplasm, extracellular space, and others, but downregulates IG proteins localized in nuclear and plasma membranes, and LIUS downregulates phosphatases. (3) LIUS-modulated IGs act partially via several important pathways of reactive oxygen species (ROS), reverse signaling of immune checkpoint receptors B7-H4 and BTNL2, inflammatory cytokines, and static or oscillatory shear stress and heat generation, among which ROS is a dominant mechanism. (4) LIUS upregulates trained immunity enzymes in lymphoma cells and downregulates trained immunity enzymes and presumably establishes trained tolerance in BM cells. (5) LIUS modulates chromatin long-range interactions to differentially regulate IGs expression in cancer cells and noncancer cells. …”
Get full text

Virological Aspects of COVID-19 in Patients with Hematological Malignancies: Duration of Viral Shedding and Genetic Analysis by Asma Themlaoui, Massimo Ancora, Kais Ghedira, Yosra Mhalla, Manel Hamdoun, Maroua Bahri, Lamia Aissaoui, Raihane Ben Lakhal, Adriano Di Pasquale, Cesare Camma, Olfa Bahri

“…In this prospective study, we aimed to determine the duration of excretion of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 37 Tunisian patients with hematological malignancies (40.5% with lymphoma and 37.8% with leukemia). In order to investigate the accumulation of viral mutations, we carried out genetic investigation on longitudinal nasopharyngeal samples using RT-PCR and whole-genome sequencing. …”
Get full text

Bioinformatic characterization of STING expression in hematological malignancies reveals association with prognosis and anti-tumor immunity by Xiang-mei Wen, Xiang-mei Wen, Xiang-mei Wen, Zi-jun Xu, Zi-jun Xu, Zi-jun Xu, Ji-chun Ma, Ji-chun Ma, Ji-chun Ma, Min-jie Zhang, Min-jie Zhang, Min-jie Zhang, Ye Jin, Ye Jin, Jiang Lin, Jiang Lin, Jiang Lin, Jun Qian, Jun Qian, Yuan-yuan Fang, Yuan-yuan Fang, Yuan-yuan Fang, Shu-yu Luo, Shu-yu Luo, Shu-yu Luo, Zhen-wei Mao

“…Cytolytic score and STING expression were positively correlated in some hematological tumors, especially chronic lymphocytic leukemia and mantle cell lymphoma. Interestingly, STING expression was negatively correlated with TIDE biomarkers in AML, suggesting that AML patients with a high STING expression level may benefit from immunologic treatment. …”
Get full text

Diagnostics and treatment of Helicobacter pylori infection in adults: Clinical guidelines of the Russian gastroenterological association by V. T. Ivashkin, I. V. Mayev, T. L. Lapina, A. A. Sheptulin, A. S. Trukhmanov, Ye. K. Baranskaya, R. A. Abdulkhakov, O. P. Alekseyeva, S. A. Alekseyenko, N. N. Dekhnich, R. S. Kozlov, I. L. Klyaritskaya, N. V. Korochanskaya, S. A. Kurilovich, M. F. Osipenko, V. I. Simanenkov, A. V. Tkachev, I. B. Khlynov, V. V. Tsukanov

“…Indications for obligatory antihelicobacter therapy include stomach and a duodenum peptic ulcer (PU), stomach MALT-lymphoma, early gastric cancer with endoscopic resection. …”
Get full text

Therapeutic benefit of the dual ALK/FAK inhibitor ESK440 in ALK-driven neuroblastoma by Seema Chugh, Jean C. Tien, Jennifer Hon, Carson Kenum, Rahul Mannan, Yunhui Cheng, Chi Chiang Li, Zainab I. Taher, Andrew D. Delekta, Pushpinder Singh Bawa, Ingrid J. Apel, Stephanie J. Miner, Xuhong Cao, Rohit Mehra, Saravana M. Dhanasekaran, Yuanyuan Qiao, Rajen Mody, Arul M. Chinnaiyan

“…In addition, a proportion of high-risk patients harbor amplification or activating mutations in anaplastic lymphoma kinase (ALK), and co-occurrence of ALK mutations and MYCN amplification have been associated with aggressive disease. …”
Get full text

Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y glo... by Mieke Van Hemelrijck, Salvatore Grisanti, Avinash Aujayeb, Martin Forster, Giannis Mountzios, Andrea Napolitano, Bruno Vincenzi, Joachim G J V Aerts, Marina Garassino, Valter Torri, Solange Peters, Alex Friedlaender, Alfredo Addeo, Giuseppe Lo Russo, Roberto Ferrara, Diego Signorelli, Alessandro Russo, So Yeon Kim, Jarushka Naidoo, Scott Gettinger, Heather Wakelee, Martin Sebastian, Mark Awad, Abdul Rafeh Naqash, Alessio Cortellini, Raffaele Giusti, Michele De Tursi, Federica Zoratto, Marco Russano, Rita Chiari, Biagio Ricciuti, Andrea De Giglio, Alain Gelibter, Giuseppe Tonini, Amin H Nassar, Alessandra Curioni-Fontecedro, Eleni Karapanagiotou, Emilio Bria, Jack Bell, Paolo Bironzo, Joao V Alessi, Alessandro Morabito, David J Pinato, Francesco Passiglia, Carlo Genova, Francesca Mazzoni, Alessandro Inno, Francesco Grossi, Luca Cantini, Lorenza Landi, Luigi Della Gravara, Margarita Majem, Uma Mukherjee, Federica Biello, Alessandro Leonetti, Annalisa Guida, Marianna Macerelli, Gabriele Minuti, Giulio Metro, Thomas Newsom-Davis, Eleni Josephides, Andrea Camerini, Elisa Roca, David O’Reilly, Mingjia Li, Laura Mezquita, Teresa Gorría, Claudia A M Fulgenzi, Lauren Young, Joel W Neal, Javier Baena, Francesco Pantano, Jacobo Rogado, Mary Jo Fidler, Teresa Beninato, Federica Pecci, Alessandro Di Federico, Kazuki Takada, Leonardo Brunetti, Talal El Zarif, Laura Moliner, Alberto Servetto, Sukumar Kalvapudi, Sai Yendamuri, Edoardo Garbo, Giuseppina Rita Di Fazio, Monica Loza, Ritujith Jayakrishnan, Michele Montrone, Nichola O Awosika, Bartlomiej Tomasik, Maximilian Rost, Isabelle Monnet, Francesco Agustoni, Artur Katz, Dwight Hall Owen, Michele Ghidini, Armida D’Incecco, Gianpaolo Spinelli, Monica Verrico, Manuel Dupont, Rafael Di Marco Barros, Diego Luigi Cortinovis, Chiara Bennati, Frank Aboubakar Nana, Anne-Marie Dingemans, Taher Abu Hejleh

“…To further assess the reproducibility of clinical trial results, we reconstructed the “KN024 look-alike” cohort by excluding patients with an Eastern Cooperative Oncology Group-performance status (ECOG-PS)≥2, those requiring corticosteroids with doses ≥10 mg of prednisolone/equivalent, patients with positive/unknown epidermal growth factor receptor/anaplastic lymphoma kinase genotype, and those with pre-existing autoimmune disease. …”
Get full text